|Podcasts|January 19, 2011
Build A Drug's Value in Early
Advertisement
Build a Drug's Value in Early
Mark Clein, President of United BioSource (UBC), discusses the company’s recent acquisition of Total Healthcare Group, a London-based consultancy on payer research, strategic planning and global value dossiers for the biopharma industry. Clein also discusses the current focus on comparative effectiveness, evidence-based research and value in medicines and how that impacts the Phase I through III development environment.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Inside the Recruitment Bottlenecks Driving Trial Delays
2
FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains
3
Takeda’s Phase III TIDES Trial Confirms Long-Term Efficacy and Safety of Qdenga Dengue Vaccine
4
ACT Brief: Tech-Driven Data Strategies and Long-Term Vaccine Success
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
